Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more
Market Cap & Net Worth: Diamyd Medical AB (publ) (DMYD-B)
Diamyd Medical AB (publ) (ST:DMYD-B) has a market capitalization of $162.45 Million (Skr1.82 Billion) as of March 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #16654 globally and #156 in its home market, demonstrating a -5.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diamyd Medical AB (publ)'s stock price Skr13.60 by its total outstanding shares 133996603 (134.00 Million).
Diamyd Medical AB (publ) Market Cap History: 2015 to 2026
Diamyd Medical AB (publ)'s market capitalization history from 2015 to 2026. Data shows growth from $70.47 Million to $162.45 Million (5.55% CAGR).
Index Memberships
Diamyd Medical AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$4.63 Billion | 3.10% | #6 of 281 |
Weight: Diamyd Medical AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diamyd Medical AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diamyd Medical AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1034.59x
Diamyd Medical AB (publ)'s market cap is 1034.59 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.24 Million | $757.00K | -$32.01 Million | 103.35x | N/A |
| 2017 | $40.37 Million | $922.00K | -$25.55 Million | 43.79x | N/A |
| 2018 | $82.42 Million | $726.00K | -$43.95 Million | 113.52x | N/A |
| 2019 | $297.42 Million | $1.57 Million | -$36.73 Million | 189.68x | N/A |
| 2020 | $368.49 Million | $341.00K | $9.71 Million | 1080.62x | 37.95x |
| 2021 | $176.78 Million | $253.00K | $60.05 Million | 698.74x | 2.94x |
| 2022 | $159.70 Million | $454.00K | -$103.52 Million | 351.76x | N/A |
| 2023 | $78.48 Million | $546.00K | -$116.07 Million | 143.73x | N/A |
| 2024 | $196.37 Million | $130.00K | -$151.85 Million | 1510.54x | N/A |
| 2025 | $134.50 Million | $130.00K | -$169.78 Million | 1034.59x | N/A |
Competitor Companies of DMYD-B by Market Capitalization
Companies near Diamyd Medical AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Diamyd Medical AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Diamyd Medical AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Diamyd Medical AB (publ)'s market cap moved from $70.47 Million to $ 162.45 Million, with a yearly change of 5.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr162.45 Million | +20.78% |
| 2025 | Skr134.50 Million | -31.51% |
| 2024 | Skr196.37 Million | +150.23% |
| 2023 | Skr78.48 Million | -50.86% |
| 2022 | Skr159.70 Million | -9.66% |
| 2021 | Skr176.78 Million | -52.03% |
| 2020 | Skr368.49 Million | +23.90% |
| 2019 | Skr297.42 Million | +260.87% |
| 2018 | Skr82.42 Million | +104.14% |
| 2017 | Skr40.37 Million | -48.40% |
| 2016 | Skr78.24 Million | +11.02% |
| 2015 | Skr70.47 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Diamyd Medical AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $162.45 Million USD |
| MoneyControl | $162.45 Million USD |
| MarketWatch | $162.45 Million USD |
| marketcap.company | $162.45 Million USD |
| Reuters | $162.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.